Keyphrases
Pathological Complete Response
100%
Microsatellite Instability-high (MSI-H)
100%
Neoadjuvant
100%
Nivolumab Plus Ipilimumab
100%
Ampullary Adenocarcinoma
100%
Blood Tumor mutational Burden
66%
Lynch Syndrome
50%
Pancreatic Ductal Adenocarcinoma
33%
Optimal Treatment
33%
Genetic Profile
33%
Genomic Profiling
33%
Complete Genomics
33%
Ampullary
33%
PD-L1 Expression
33%
MSH2 Gene
33%
Adverse Effects
16%
Immunohistochemistry
16%
Disease Progression
16%
Resection
16%
Next-generation Sequencing
16%
Chemotherapy
16%
Oxaliplatin
16%
Irinotecan
16%
Predictive Biomarker
16%
Leucovorin
16%
Ipilimumab
16%
Nivolumab
16%
Periampullary Cancer
16%
Epigastric Pain
16%
Pancreaticoduodenectomy
16%
Deficient Mismatch Repair (dMMR)
16%
FOLFIRINOX
16%
Fluorouracil
16%
Medicine and Dentistry
Adenocarcinoma
100%
Ipilimumab
100%
Nivolumab
100%
Tumor Mutational Burden
57%
Hereditary Nonpolyposis Colorectal Cancer
42%
Programmed Death-Ligand 1
28%
Microsatellite Instability
28%
Pancreas Adenocarcinoma
28%
Biological Marker
14%
Immunohistochemistry
14%
Carcinoma
14%
Disease Exacerbation
14%
Next Generation Sequencing
14%
Irinotecan
14%
Oxaliplatin
14%
Fluorouracil
14%
Body Weight
14%
Folinic Acid
14%
DNA Mismatch Repair
14%
Epigastric Pain
14%
Pancreaticoduodenectomy
14%
Adverse Effect
14%
Side Effect
14%